It will be of great interest whether pharmacological therapeutics, such as targeting cardiac Alox12/15 as an auxiliary intervention, will ameliorate the severity of cellular hypertrophy and fibrotic changes in FC with IVS4+919 G>A mutation, especially in the late stage patients with myocardial-fibrosis and insensitive to ERT. The gene discussed is ALOX12; the disease is Myocardial fibrosis.